

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Fish Oil and Inflammation: A Perspective on the Challenges of Evaluating Efficacy in *Trypanosoma cruzi* Infection

Maria Isabel Lovo-Martins, Marli Cardoso Martins-Pinge and Phileo Pingue-Filho

Abstract

Parasitic diseases constitute a big problem of ill health in both the tropics and subtropics as well as in more temperate climates and have been targeted by the Centers for Disease Control and Prevention (CDC) as priorities for public health in the USA. Parasitic infections can be caused by three types of organisms: protozoa, helminths and ectoparasites. They subsist on the host's nutrients at the host's expense. Effectively combating infections caused by parasites is essential for the survival of the organism. In this effort, cells and molecules of the immune system are susceptible to the modulating influence of fatty acids. The primary purpose of this chapter is to present a critical review of the multiple effects of fish-oil on *Trypanosoma infection*.

Keywords: *Trypanosoma cruzi*, Chagas disease, *n*-3 PUFAs, dietary fish oil, disease control

1. Introduction

Chagas disease, also known as American trypanosomiasis, is caused by infection with the hemoflagellate protozoa *Trypanosoma cruzi*. This disease was first described in 1909, by the epidemiologist Carlos Justiniano Chagas. In this pioneering work, not only the etiological agent *Trypanosoma cruzi* was described, but also its evolutionary forms, life cycle, epidemiology and clinical manifestations of the disease was fully reported [1]. More than a century after this discovery, it is estimated that Chagas disease still affects around 6–7 million people worldwide, especially in Latin America, with more than 10,000 deaths annually [2]. Currently, Chagas Disease is considered as a neglected tropical disease by the World Health Organization [3].

The progression of Chagas disease is characterized by the occurrence of three phases: acute, indeterminate and chronic. Survival during the acute phase of infection requires an inflammatory response involving cells of innate immunity, such as macrophages, dendritic cells and natural killers whereas in the chronic phase the T-lymphocyte-mediated immunity maintains parasite replication under control [4]. However, evidence suggests that the exacerbated inflammatory response of the host is one of the most determinant factors in the progression of Chagas disease, along with the virulence and tropism of the strain [5, 6].

During *T. cruzi* infection—as in other infections—the immune system acts to protect the host from infectious agents and the nutrient status is an important factor contributing to immune response [7]. Between the components from the diet, fatty acids found in oils and oily food have an important role not only in the structure of cell membranes, energy source or as hormones precursors [8], but acts directly as modulators of the immune response [9]. Specifically, the consumption of fatty acids from the family of omega-3 polyunsaturated fatty acids (*n*-3 PUFAs), found in large amounts in fish oil, has been associated with anti-inflammatory and immunomodulatory effects [10]. Taking this into account, an important issue to be raised is the effect of *n*-3 PUFAs supplementation on infectious diseases, such as Chagas disease, where an efficient—but controlled inflammation—is necessary and important for host defense [11].

Currently, daily oral supplementation with *n*-3 PUFAs is recommended by the American College of Cardiology and American Heart Association as an important adjuvant in the treatment of heart failure [12]. In the same sense, daily oral supplementation with *n*-3 PUFAs is recommended by the Brazilian Directive on Dyslipidemias and Prevention of Atherosclerosis, updated in 2017 by the Brazilian Society of Cardiology (2–4 g daily), as an important complement in the prevention of atherosclerosis and its cardioprotective benefits [13]. Despite the recognized relevance of *n*-3 PUFA supplementation in the supplementary treatment of cardiovascular diseases, and considering the important cardiac compromises that may occur during the chronic phase of Chagas disease, supplementation with *n*-3 PUFAs may in fact represent a perspective for the additional treatment of patients affected by Chagas disease. However, the immunomodulatory effects of the dietary supplementation with *n*-3 PUFAs and the relationship with the host response and resistance to *T. cruzi* infection should be carefully considered.

2. Polyunsaturated fatty acids

Polyunsaturated fatty acids (PUFAs) are a class of fatty acids with 18–22 carbons (C18–C22) containing two or more double bonds in the carbon chain. The most important PUFAs for human health and nutrition are the omega-6 (*n*-6) and omega-3 (*n*-3) families. The classification of the fatty acids between this families is made considering the position of the first double bond counting from the methyl end of the fatty acid chain [14]. Linoleic acid (LA) is considered the parent fatty acid of the *n*-6 PUFAs family, while α -linolenic acid (ALA) is considered the parent fatty acid of the *n*-3 PUFAs family. Both LA and ALA cannot be made by humans or other mammals, thus they are considered essential fatty acids and have to be supplied in the diet [15].

The *n*-6 PUFA LA (18:2*n*-6) could be found naturally the seeds of most plants except for cocoa, coconut, and palm. On its turn, the *n*-3 PUFA ALA (18:3*n*-3) is found in the seeds of flax, rape, chia, perilla, walnuts (and their vegetable oils) or even chloroplast of green leafy vegetables. In the body, both LA and ALA are metabolized to longer-chain fatty acids of 20 or 22 carbons [15, 16]. LA is metabolized to arachidonic acid (AA), a long chain *n*-6 PUFA (LC *n*-6 PUFA) whereas ALA is metabolized to eicosapentaenoic acid (EPA, 20:5*n*-3) and docosahexaenoic acid (DHA, 22:6*n*-3), a long chain *n*-3 PUFAs (LC *n*-3 PUFA). This reaction occurs through the actions of elongases enzymes, that increase the chain length; and desaturases enzymes, which add extra double bonds to the carboxyl end of the fatty acid, increasing the degree of unsaturation [17]. Humans and others mammals could convert LA in AA; and ALA in EPA and DHA, however this process is slow.

Although there is a competition between *n*-6 PUFAs and *n*-3 PUFAs for the desaturation enzymes, which prefer the ALA instead the LA, the Western diet provides higher amounts of LA than ALA, being the AA the main unsaturated long-chain fatty acid produced [18]. Therefore, the most efficient way to increase the amount of LC *n*-3 PUFAs in the body is through directly ingestion of primary sources EPA and DHA, as the seafood. The LC *n*-3 PUFAs are found in high amounts in most seafood, especially in oily fish, in the blubber and tissues of sea mammals like seals and whales or even in supplements like fish oils, cod liver oil, krill oil, algal oils and in pharmaceutical grade preparations [10].

3. Immunomodulatory effects of long chain *n*-3 polyunsaturated fatty acids

Experimental assays have shown that diet supplementation with LC *n*-3 PUFAs results in powerful anti-inflammatory and immunomodulatory activities in a range of diseases, such as autoimmune [19], inflammatory bowel disease [20], rheumatoid arthritis [21] and even infectious diseases [22–25]. There are also clinical trials in human patients associating the use of supplements rich in LC *n*-3 PUFAs with the evolution of inflammatory diseases [26] and infections, such as sepsis [27]. Studies in patients with rheumatoid arthritis are those that present better results, with several tests showing reduction of symptoms, such as morning swelling, pain and stiffness [28].

Inflammation is a fundamental component of the body response to infections or injuries that involves the interactions among many different cell types. The leucocytes are cells from immune system found in the peripheral blood and lymph tissue that actively participate in the inflammation, being specially involved in body defense and protection [29]. Typically, inflammation is transient, exerting a protective role in the body. However, when the inflammation does not end and the acute response become chronic, this uncontrolled response leads to more injury [29]. Therefore, inflammation is the pathological mechanism behind many chronic diseases, and that is why the immunomodulatory effects of LC *n*-3 PUFAs are considered to be potentially beneficial.

Some mechanisms of the immune response modulation by LC *n*-3 PUFAs are already known, such as modification of function and composition of immune system cell membranes, change in the pattern of eicosanoids produced and in the cytokine profile, regulation of gene expression and proliferation of T lymphocytes [30]. The leukocyte membrane phospholipids from humans consuming a Western diet typically have 15–20% of AA, 0.5–1% of EPA and 2–3% of DHA. When fish oil rich in LC *n*-3 PUFAs are incorporated to the diet, increased amounts of EPA and DHA are incorporated in these phospholipids in a time and dose dependent fashion, and it occurs at the expense of AA [31, 32]. These changes in membrane fatty acid composition subsequently modify the cell-membrane fluidity, production of eicosanoids and the formation of lipid rafts [17, 33].

4. Long chain *n*-3 PUFAs and *Trypanosoma cruzi* infection

Infection with *T. cruzi* causes a strong inflammatory reaction at the inoculation site and, later, in the myocardium [34]. Approximately one-third to one-half of patients with indeterminate disease will eventually develop chronic Chagas cardiomyopathy (CCC). CCC results from the combined effects of persistent parasitism, parasite-driven tissue inflammation, micro-vascular and neurogenic dysfunction, and autoimmune responses triggered by the *T. cruzi*-infection [34, 35].

There are few studies on the effects of increased consumption of LC *n*-3 PUFAs rich foods as well as the long-term effects of LC *n*-3 PUFAs on inflammatory profile and clinical outcomes in CCC. Recently, a group of Brazilian researchers reported that patients aging >18 years, with a diagnosis of CCC, that received LC *n*-3 PUFAs capsules (1.8 g EPA and 1.2 g DHA) during an 8-week period, presented modifications in the lipid and inflammatory profile, demonstrated by a decrease in triglycerides and improvements on IL-10 concentration [36]. The same group had already supposed in 2013 that the anti-inflammatory action of LC *n*-3 PUFAs may have beneficial effects on chronic chagasic cardiomyopathy, and could be translated into a less severe progression of cardiomyopathy, with subsequent reduction in morbidity [37].

In mice, the resistance to acute infection has been shown to be dependent on interferon IFN- γ that activates macrophages to produce nitric oxide (NO) and kill the obligate intracellular amastigote form of the parasite [38–40]. In addition, TNF- α provides a second signal stimulating NO production and anti-*T. cruzi* activity in IFN- γ -activated macrophages.

TNF- α is a cytokine that appears rapidly after infections or lesions, playing a key role in fighting invasive pathogens. However, excessive TNF- α production is related to mortality and morbidity in sepsis [41], meningitis [42] and malaria [43]. Although many of the studies about TNF- α modulation by treatment with LC *n*-3 PUFAs indicate a suppressive effect on this cytokine production, there are studies reporting an increase in cytokines production by treatment with LC *n*-3 PUFAs. Increased TNF- α production was reported by macrophages stimulated *in vitro* with LPS [25]. Dietary supplementation with fish oil on experimental *Klebsiella pneumoniae* infection and in brain-infection by *Plasmodium berghei* led to increased *ex vivo* production of TNF- α and IL-1 α by *in vitro* LPS-stimulated macrophages [24]. Also, the *in vivo* treatment with fish oil increased TNF- α plasma levels in mice infected with *Listeria monocytogenes* in the first 24 hours of infection, being lower in later times [44]. In addition, specifically in *T. cruzi* infected-mice that were supplemented with fish oil rich in LC *n*-3 PUFAs it was related increased TNF- α production by the spleen cells [22].

The first work on the *in vivo* effects of PUFAs supplementation on *T. cruzi* infection was published in 1958 by Godfrey and coworkers. They showed that oral supplementation with cod liver oil, rich in LC *n*-3 PUFA, associated with vitamins A and D, suppressed mice infections with *T. congolense* and *T. vivax*, but showed no effect on mice infected with *T. cruzi* or *T. brucei* [45]. However, when vitamin E was used together with cod liver oil, these adverse effects on host resistance on *T. congolense* and *T. vivax* infection were reversed, suggesting that diet-induced oxidative stress and vitamin E deficiency were central to this particular diet-infection relationship.

In 1995, Takeda and collaborators reported that daily oral administration of the LC *n*-3 PUFA EPA, present in great amounts in fish oil, greatly diminished host survival following an experimental infection with *T. cruzi* [46]. As in the work of 1958, they included vitamin E in EPA treatment, in order to try to avoid the oxidative stress problem. The authors reported that their EPA-treatment failed to impact tissue parasitism, but was associated with elevated capacity to produce the inflammatory cytokine TNF- α .

In contrast, more recently our research group has described that oral supplementation with fish oil on *T. cruzi* infected-mice did not change the mortality rate, but it did alter the course of parasitemia, as well as other important host responses, such the increased TNF- α production [22]. In *T. cruzi* infected-mice that were supplemented with fish oil rich in LC *n*-3 PUFAs we observed a transient, but substantial, increase in peak circulating parasitic load at the 7th day post infection. At the 12th day post infection, these fish oil-treated mice had similar

levels of parasitemia in the blood compared to controls groups (mice treated with saline or corn oil). Surprisingly, besides the high peak of parasitemia, the mice that were treated with fish oil rich in LC *n*-3 PUFAs showed significantly fewer parasites in their cardiac tissue at the 12th day post infection (**Figure 1**) compared to mice treated with saline or corn oil. The oral supplementation with corn oil was used as an alternative fat source rich in the *n*-6 PUFA linoleic acid but poor in LC *n*-3 PUFAs [22].




Figure 1.
Effects of FO supplementation on cardiac parasitism. From 15 days before *T. cruzi* infection until the 12th day post infection, C57BL/6 mice were supplemented by gavage with 0.6% (v/w) saline, corn oil, or menhaden fish oil. C57BL/6 mice were infected with 5×10^3 blood trypomastigotes *T. cruzi* (Y strain). Cardiac parasitism (A): three heart sections were counted for each animal, and the results are expressed as means \pm SEM of three sections from five animals per group and are representative of two independent experiments. Cardiac tissues (B) were examined by hematoxylin and eosin staining from uninfected mice (1) on day 12 after *T. cruzi* infection (2 and 3). Original magnifications were 400 \times (1 and 2) and 1000 \times (3). Original publication [22].

In humans, as in some experimental animals, *T. cruzi* infection is associated with anemia, thrombocytopenia, leukopenia and bone marrow hypoplasia [47–50]. Dietary supplementation with fish oil had no effect on the anemia of *T. cruzi*-infected mice [22], a finding that contrasts with the improvement in malaria-induced anemia reported by the treatment with LC *n*-3 PUFAs [46]. However, thrombocytopenia and leukopenia were less severe in *T. cruzi*-infected mice orally treated with fish oil [22].

The production of eicosanoids represents an important role in the regulation between the host's immune response and the establishment of *T. cruzi* infection (**Figure 2A**). Eicosanoids are lipid mediators of inflammation which include prostaglandins (PG), thromboxanes (TX), leukotrienes (LT) and lipoxins (LX). The initial substrate for the synthesis of eicosanoids is the lipids present in the membrane phospholipids of cells involved with inflammatory processes. In individuals with a regular western diet, AA is the most prevalent fatty acid in the inflammatory cell membrane, and it is usually the main substrate for the synthesis of eicosanoids, giving rise to series 2-series prostaglandins and thromboxanes and 4-series leukotrienes and lipoxins [30].

Acute *T. cruzi* infection in murine models is characterized by cardiac lesions associated by high levels of PGE₂ [51]. During acute *T. cruzi* infection, both PGE₂ and its EP₂ receptor are involved in inflammation and cardiac inflammatory infiltrate [52], as leukotrienes, that is important for the local production of NO and cardiac parasitism control [53, 54]. Additionally, plasma PGE₂, TBX₂ e 6-oxo-PGF_{10α} levels are increased in murine models of acute infection [55, 56]. In addition to cardiac effects, PG are associated with immunosuppression of infected animals, with reduction in lymphocyte proliferation, on TNF-α levels, and in the microbicidal functions of macrophages [57, 58].

In vitro assays have shown that the phagocytosis of apoptotic cells by macrophages during *T. cruzi* infection potentiates the release of PGE₂ and transforming growth factor-beta (TGF-β) by these cells. These macrophages become refractory to inflammatory cytokines, consequently decreasing NO production and allowing parasite survival and growth even in an immune response environment [59]. Also, the pharmacological inhibition of the COX enzyme with aspirin in macrophages decreased the trypomastigotes internalization in these cells, with increase of interleukin-1 (IL1-β), NO and lipoxins [60]. In addition, PGE₂ elicits signaling pathways capable of instantaneously inhibiting NLRP3 inflammation activation [61]. This may be relevant in the context of *T. cruzi* infection, since the activation of the inflammatory complex NLRP3 and caspase-1 is important for parasite control during the acute phase of infection, leading to activation of trypanocidal activities in macrophages, as NO production [62].

Although PGE₂ is important for the parasite survival at the beginning of infection, the *in vivo* pharmacological blockade of COX enzymes during the acute phase of *T. cruzi* infection leads to higher levels of parasitemia, lower survival rates of experimental mice and increased cardiac parasitism [63–65]. However, COX blockade with aspirin already in the chronic phase (60 days after infection) does not cause an increase in parasitemia or mortality, but is associated with an improvement in the cardiac ejection fraction [64].

Confirming the relevance of inflammatory-lipid mediators during *T. cruzi* infection is the fact that the parasite itself synthesizes prostaglandins and thromboxanes (TX) [66]. Infective stages of *T. cruzi* have the enzyme phospholipase A-1, important for the release of fatty acids (such as AA) from the membranes and for eicosanoid synthesis, as represented in **Figure 2A**. From AA, *T. cruzi* preferentially




Figure 2. Mechanism and effects of PUFAs n-3 PUFAs supplementation on *Trypanosoma cruzi* infection. 1—The traditional western diet provides to immune cells great amounts of n-6 PUFAs arachidonic acid and linoleic acid, while a diet supplementation with LC n-3 PUFAs results in eicosapentaenoic acid and docosahexaenoic acid incorporation into immune cells plasma membrane phospholipids [31, 32]. 2—*T. cruzi* infection trigger inflammatory stimulus, as the expression of cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes [53, 55]. The enzyme phospholipase A₂ (PLA₂) removes fatty acids from the membrane phospholipids, mainly arachidonic acid (AA) in cells from western diet and mainly eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) from n-3 diet. 3—The enzymes COX and LOX uses the free fatty acids for eicosanoids synthesis. When AA is used as substrate 2-series prostaglandins/thromboxanes and 4-series leukotrienes/lipoxins are formed. When the substrate is EPA or DHA, a switch in the class of eicosanoids produced occurs, being produced 3-series prostaglandins/thromboxanes and 5-series leukotrienes/lipoxins [30], as well mediators that act in the resolution of inflammation: E-series resolvins generated from EPA, D-series resolvins from DHA, and protectins and maresins from DHA [72, 73]. 4—In the acute phase of infection, the high production of prostaglandin E₂ (PGE₂) leads to a transient immunosuppression, with decreased TNF-α production by the host [57]. The immune cells from n-3 diet produce lower amounts of PGE₂, and consequently more TNF-α [22]. 5—The thromboxane A₂ (TXA₂) produced during *T. cruzi* infection is associated with a control mechanism of parasite proliferation and less exposure to immune system [67]. The decreased TXA₂ production that occurs in cells from n-3 PUFAs diet could explain the increased parasitemia that were previously observed in vivo, leading to more *T. cruzi* exposition to immune system [22]. 6—Effects of in vivo supplementation of experimental mice during acute *T. cruzi* infection [22]. 7—Effects of in vivo supplementation of human patients with chronic Chagas cardiomyopathy [37]. Original publication [22].

synthesizes TXA₂, in addition to small amounts of PGE_{2α} [67]. During acute infection, TXA₂ produced by the parasite acts on the vascular endothelium creating an inflammatory phenotype, increasing the expression of adhesion molecules and directly participating in the parasitemia control and host survival. The absence of TXA₂ receptor in infected-host cells leads to large cellular parasitism, when compared to cells that have the receptor. This indicates that *T. cruzi* has a self-regulated mechanism that controls its proliferation through TXA₂ [67]. The effects of both TXA₂ produced by the parasite and the PGE₂ produced by the host create an immunomodulatory environment that favors the survival of the host, an indispensable factor for the survival of the parasite and maintenance of the chronic phase of the infection [63, 67].

When incorporated into cell plasma membrane, LC *n*-3 PUFAs competitively inhibit the formation of eicosanoids from AA by the enzymes cyclooxygenase (COX) and lipoxygenase (LOX), being produced, from the fatty acids EPA and DHA, 3-series prostaglandins and thromboxanes and 5-series leukotrienes and lipoxins. These eicosanoids produced from the EPA and DHA have less inflammatory activity [68, 69]. This effect occurs in part due to the reduction of AA available, but also due to a direct action of the EPA decreasing the activity and expression of the COX-2 enzyme, that is responsible for the synthesis of prostaglandins after an inflammatory stimulus [70].

We have shown that fish oil supplementation decreased the production of PGE₂ in mice uninfected (**Figure 3A**) and infected with *T. cruzi* (**Figure 3B**) [22], as also represented in **Figure 2B**. In addition, as discussed above, it is reported in the scientific literature that LC *n*-3 PUFA supplementation promotes the production of 3-series thromboxanes, rather than the production of 2-series thromboxanes, a lipid mediator described as important for the regulation and continuity of infection by *T. cruzi* [67]. The use of LC *n*-3 PUFAs to modulate the production of eicosanoids exhibit relevant differences when compared to the use of pharmacological inhibitors of COX isoforms. While pharmacological COX blockade results in a marked decrease in eicosanoid production, the LC *n*-3 PUFAs acts promoting a change in the class of eicosanoids produced, without, however, completely abolishing those produced from AA. In addition, the inflammatory pro-resolution lipid mediators resolvins, maresins and protectins produced from the LC *n*-3 PUFAs DHA and EPA could control the tissue injury resulting from the exacerbated activation of the immune response [30]. Pro-resolvins are a class of lipid mediators that act in the resolution of inflammation [71]. E-series resolvins (RvE) are generated from EPA, D-series resolvins (RvD) from DHA, and protectins and maresins from DHA. The synthesis of these pro-resolvins also involves the COX and LOX pathway [72, 73].

Recently was demonstrated that trypomastigotes and amastigotes of *T. cruzi* produce the pro-resolving lipids RvD1, RvD5, and RvE2. It has been reported that plasma RvD1 levels are elevated in *T. cruzi* infected mice and, at least in part, it is possible that this RVD1 is from the parasite itself. This mechanism suggests another way of how the parasite can modulate the environment in its favor. This modulation of the immune response by the parasite may be important and contribute to the perpetuation of the infection into the chronic phase [74].

Therefore, the elucidation of the more specific mechanisms involved with the protective effects of *n*-3 PUFAs on *T. cruzi* infection (**Figure 2C**) are important aspects to be investigated. Considering the discussion presented here, as well as all points raised in the scientific literature, it is reasonable to consider that the immune modulation exerted by LC *n*-3 PUFAs supplementation actually favors the host and may represent a perspective for the supplementary treatment of patients affected by Chagas disease.




Figure 3. Effects of fish oil supplementation on production of PGE₂ by spleen cells from mice infected with *T. cruzi*. From 15 days before *T. cruzi* infection to the 7th dpi, C57BL/6 mice were supplemented by gavage with 0.6% (v/w) PBS, corn oil, or fish oil. C57BL/6 mice were infected with 5×10^3 blood trypomastigotes *T. cruzi* (Y strain). Splenocytes (5×10^6 cells/well) from uninfected (A) or *T. cruzi*-infected mice (B) were cultured with and without *T. cruzi* antigen (Tc-Ag). Supernatants were harvested after 8 hours, and PGE₂ was quantified in supernatants by EIA. The results are expressed as means \pm SEM from four animals per group and are representative of two independent experiments. Means not sharing letter are significantly different ($P < 0.05$, 2-way ANOVA with Bonferroni post-test). Original publication [22].

5. Conclusion

The immunomodulatory effects of long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) are currently widely known. Dietary supplementation with LC n-3 PUFAs has been used as a complementary treatment in inflammatory diseases. However, the effects of daily supplementation with LC n-3 PUFAs on host resistance to infectious disease, such as the *T. cruzi* infection, are still poorly understood. Studies using a well-established mouse model of this human disease showed that fish oil supplementation improves the clinical course of *T. cruzi* infection during the acute phase of infection. In fact, the potential benefits of LC n-3 PUFAs supplementation in humans have been the subject of recent clinical trials. The

modulation of the immune response by LC *n*-3 PUFAs, mainly through the change in eicosanoids patterns produced during *T. cruzi* infection, could be one mechanism that results in improvement of the host response. However, more studies are necessary to determine whether or not oral supplementation with LC *n*-3 PUFA could benefit humans diagnosed with Chagas disease.

Acknowledgements

Funding: This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES) Finance Code 001, CNPq (grant Edital Universal 14-2014, research fellowships for PP-F (CNPq 307787/2015-0), MM-P (CNPq 307544/2016-8) and MILM (PNPD-Capes 22921091) and Fundação Araucária (grant 419-2009).

Conflict of interest

The authors declare that there are no conflicts of interest.

Notes/thanks/other declarations

This study would have been impossible without the aid and support of Dr. Kevin Fritsche Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, 65,211, Missouri, USA.

Author details


Maria Isabel Lovo-Martins¹, Marli Cardoso Martins-Pinge²
and Phileno Pingue-Filho^{1*}

¹ Department of Pathological Sciences, Laboratory of Experimental Immunopathology, Biological Sciences Center, State University of Londrina, Londrina, Paraná, Brazil

² Department of Physiological Sciences, Biological Sciences Center, State University of Londrina, Londrina, Paraná, Brazil

*Address all correspondence to: pingefilho@uel.br

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Chagas C. Nova tripanozomíase humana: estudos sobre a morfologia e o ciclo evolutivo do *Schizotrypanum cruzi* n. gen., n. sp., agente etiológico de nova entidade morbida do homem. *Memórias do Instituto Oswaldo Cruz*. 1909;**1**:159-218
- [2] WHO. Chagas Disease (American Trypanosomiasis); 2017. Available from: <http://www.who.int/mediacentre/factsheets/fs340/en/>
- [3] WHO. Why are Some Tropical Diseases called “neglected”? 2012. Available from: <http://www.who.int/features/qa/58/en/>
- [4] Machado FS, Dutra WO, Esper L, Gollob KJ, Teixeira MM, Factor SM, et al. Current understanding of immunity to *Trypanosoma cruzi* infection and pathogenesis of Chagas disease. *Seminars in Immunopathology*. 2012;**34**(6):753-770. DOI: 10.1007/s00281-012-0351-7
- [5] Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. *Circulation*. 2007;**115**(9):1109-1123. DOI: 10.1161/circulationaha.106.624296
- [6] Dutra WO, Menezes CA, Magalhaes LM, Gollob KJ. Immunoregulatory networks in human Chagas disease. *Parasite Immunology*. 2014;**36**(8):377-387. DOI: 10.1111/pim.12107
- [7] Calder PC, Kew S. The immune system: A target for functional foods? *The British Journal of Nutrition*. 2002;**88**(Suppl 2):S165-S177. DOI: 10.1079/bjn2002682
- [8] Turchini GM, Nichols PD, Barrow C, Sinclair AJ. Jumping on the omega-3 bandwagon: Distinguishing the role of long-chain and short-chain omega-3 fatty acids. *Critical Reviews in Food Science and Nutrition*. 2012;**52**(9):795-803. DOI: 10.1080/10408398.2010.509553
- [9] Fritsche K. Fatty acids as modulators of the immune response. *Annual Review of Nutrition*. 2006;**26**:45-73. DOI: 10.1146/annurev.nutr.25.050304.092610
- [10] Calder PC. Very long-chain n-3 fatty acids and human health: Fact, fiction and the future. *The Proceedings of the Nutrition Society*. 2018;**77**(1):52-72. DOI: 10.1017/s0029665117003950
- [11] Anderson M, Fritsche KL. (n-3) Fatty acids and infectious disease resistance. *The Journal of Nutrition*. 2002;**132**(12):3566-3576
- [12] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology* 2013;**62**(16):e147–e239. DOI: 10.1016/j.jacc.2013.05.019
- [13] Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune AN, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose—2017. *Arquivos Brasileiros de Cardiologia*. 2017;**109**(2 Supl 1):1-76. DOI: 10.5935/abc.20170121
- [14] Ratnayake WM, Galli C. Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: A background review paper. *Annals of Nutrition & Metabolism*. 2009;**55**(1-3):8-43. DOI: 10.1159/000228994
- [15] Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. *Nutrients*. 2016;**8**(3):128. DOI: 10.3390/nu8030128

- [16] Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. *The American Journal of Clinical Nutrition*. 1991;**54**(3):438-463. DOI: 10.1093/ajcn/54.3.438
- [17] Kaur KK, Allahbadia G, Singh M. Synthesis and functional significance of poly unsaturated fatty acids (PUFA's) in body. *Acta Scientific Nutritional Health*. 2018;**2**(4):8. DOI: 10.15226/jnhfs
- [18] Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. *The American Journal of Clinical Nutrition*. 2011;**93**(5):950-962. DOI: 10.3945/ajcn.110.006643
- [19] Maalouly G, Ward C, Smayra V, Saliba Y, Aftimos G, Haddad F, et al. Fish oil attenuates neurologic severity of antiphospholipid syndrome in a mice experimental model. *Nutritional Neuroscience*. 2016;**20**:1-8. DOI: 10.1080/1028415x.2016.1206165
- [20] Hokari R, Matsunaga H, Miura S. Effect of dietary fat on intestinal inflammatory diseases. *Journal of Gastroenterology and Hepatology*. 2013;**28**(Suppl 4):33-36. DOI: 10.1111/jgh.12252
- [21] Woo SJ, Lim K, Park SY, Jung MY, Lim HS, Jeon MG, et al. Endogenous conversion of n-6 to n-3 polyunsaturated fatty acids attenuates K/BxN serum-transfer arthritis in fat-1 mice. *The Journal of Nutritional Biochemistry*. 2015;**26**(7):713-720. DOI: 10.1016/j.jnutbio.2015.01.011
- [22] Lovo-Martins MI, Malvezi AD, da Silva RV, Zanluqui NG, VLH T, NOS C, et al. Fish oil supplementation benefits the murine host during the acute phase of a parasitic infection from *Trypanosoma cruzi*. *Nutrition Research*. 2017;**41**:73-85. DOI: 10.1016/j.nutres.2017.04.007
- [23] Irons R, Anderson MJ, Zhang M, Fritsche KL. Dietary fish oil impairs primary host resistance against *Listeria monocytogenes* more than the immunological memory response. *The Journal of Nutrition*. 2003;**133**(4):1163-1169
- [24] Blok WL, Vogels MT, Curfs JH, Eling WM, Buurman WA, van der Meer JW. Dietary fish-oil supplementation in experimental gram-negative infection and in cerebral malaria in mice. *The Journal of Infectious Diseases*. 1992;**165**(5):898-903
- [25] Blok WL, Rabinovitch M, Zilberfarb V, Netea MG, Buurman WA, van der Meer JW. The influence of dietary fish-oil supplementation on cutaneous *Leishmania amazonensis* infection in mice. *Cytokine*. 2002;**19**(5):213-217
- [26] Rajaei E, Mowla K, Ghorbani A, Bahadoram S, Bahadoram M, Dargahi-Malamir M. The effect of omega-3 fatty acids in patients with active rheumatoid arthritis receiving DMARDs therapy: Double-blind randomized controlled trial. *Global Journal of Health Science*. 2015;**8**(7):18-25. DOI: 10.5539/gjhs.v8n7p18
- [27] Ferguson JF, Mulvey CK, Patel PN, Shah RY, Doveikis J, Zhang W, et al. Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers. *Molecular Nutrition & Food Research*. 2014;**58**(3):601-613. DOI: 10.1002/mnfr.201300368
- [28] Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. *The British Journal of Nutrition*. 2012;**107**(Suppl 2):S171-S184. DOI: 10.1017/S0007114512001560
- [29] Fritsche KL. The science of fatty acids and inflammation. *Advances in Nutrition (Bethesda, Md)*.

2015;6(3):293s-301s. DOI: 10.3945/an.114.006940.

[30] Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochimica et Biophysica Acta*. 2015;1851(4):469-484. DOI: 10.1016/j.bbali.2014.08.010

[31] Faber J, Berkhout M, Vos AP, Sijben JW, Calder PC, Garssen J, et al. Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. *The Journal of Nutrition*. 2011;141(5):964-970. DOI: 10.3945/jn.110.132985

[32] Yaqoob P, Pala HS, Cortina-Borja M, Newsholme EA, Calder PC. Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. *European Journal of Clinical Investigation*. 2000;30(3):260-274

[33] Calder PC, Yaqoob P, Harvey DJ, Watts A, Newsholme EA. Incorporation of fatty acids by concanavalin A-stimulated lymphocytes and the effect on fatty acid composition and membrane fluidity. *Biochemical Journal*. 1994;300(Pt 2):509-518

[34] Groom ZC, Protopapas AD, Zochios V. Tropical diseases of the myocardium: A review. *International Journal of General Medicine*. 2017;10:101-111. DOI: 10.2147/IJGM.S130828

[35] Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO. Diagnosis and management of Chagas disease and cardiomyopathy. *Nature Reviews. Cardiology*. 2012;9(10):576-589. DOI: 10.1038/nrcardio.2012.109

[36] Silva PSD, Mediano MFF, Silva G, Brito PD, Cardoso CSA, Almeida CF,

et al. Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: A randomized clinical study. *Nutrition Journal*. 2017;16(1):36. DOI: 10.1186/s12937-017-0259-0

[37] Silva PS, Sperandio da Silva GM, de Souza AP, Cardoso CS, Fonseca CA, Brito PD, et al. Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: Study protocol for a randomized controlled trial. *Trials*. 2013;14:379. DOI: 10.1186/1745-6215-14-379

[38] Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A. The microbicidal activity of interferon-gamma-treated macrophages against *Trypanosoma cruzi* involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. *European Journal of Immunology*. 1992;22(10):2501-2506. DOI: 10.1002/eji.1830221006

[39] Petray P, Rottenberg ME, Grinstein S, Orn A. Release of nitric oxide during the experimental infection with *Trypanosoma cruzi*. *Parasite Immunology*. 1994;16(4):193-199

[40] Vespa GN, Cunha FQ, Silva JS. Nitric oxide is involved in control of *Trypanosoma cruzi*-induced parasitemia and directly kills the parasite in vitro. *Infection and Immunity*. 1994;62(11):5177-5182

[41] Kaech C, Bochud PY, Calandra T. Cytokines and *Escherichia coli* Sepsis. *EcoSal Plus*. 2006;2(1):1-20. DOI: 10.1128/ecosalplus.8.8.15

[42] Armah H, Wired EK, Dodoo AK, Adjei AA, Tettey Y, Gyasi R. Cytokines and adhesion molecules expression in the brain in human cerebral malaria. *International Journal of Environmental Research and Public Health*. 2005;2(1):123-131

- [43] Perlmann P, Troye-Blomberg M. Malaria blood-stage infection and its control by the immune system. *Folia Biologica*. 2000;**46**(6):210-218
- [44] Puertollano MA, Cruz-Chamorro L, Puertollano E, Perez-Toscano MT, Alvarez de Cienfuegos G, de Pablo MA. Assessment of interleukin-12, gamma interferon, and tumor necrosis factor alpha secretion in sera from mice fed with dietary lipids during different stages of *Listeria monocytogenes* infection. *Clinical and Diagnostic Laboratory Immunology*. 2005;**12**(9):1098-1103. DOI: 10.1128/cdli.12.9.1098-1103.2005
- [45] Godfrey DG. Influence of dietary cod liver oil upon *Trypanosoma congolense*, *T. cruzi*, *T. vivax* and *T. brucei*. *Experimental Parasitology*. 1958;**7**(3):255-268
- [46] Takeda GK, Starobinas N, Marcondes MC, Mello EA, Russo M, Stolf AM. Oral administration of fish-oil induces high levels of seric TNF in *Trypanosoma cruzi* infected C57BL/6 mice. *Acta Tropica*. 1995;**60**(3): 215-219
- [47] Cardoso JE, Brener Z. Hematological changes in mice experimentally infected with *Trypanosoma cruzi*. *Memórias do Instituto Oswaldo Cruz*. 1980;**75**(3-4):97-104
- [48] Repka D, Rangel HA, Atta AM, Gavino VA, Piedrabuena AE. Experimental Chagas' disease in mice infected with one LD50 of parasite. *Revista Brasileira de Biologia*. 1985;**45**(3):309-316
- [49] Marcondes MC, Borelli P, Yoshida N, Russo M. Acute *Trypanosoma cruzi* infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: Reversal by nifurtimox treatment. *Microbes and Infection*. 2000;**2**(4):347-352
- [50] Malvezi AD, Cecchini R, de Souza F, Tadokoro CE, Rizzo LV, Pinge-Filho P. Involvement of nitric oxide (NO) and TNF-alpha in the oxidative stress associated with anemia in experimental *Trypanosoma cruzi* infection. *FEMS Immunology and Medical Microbiology*. 2004;**41**(1):69-77. DOI: 10.1016/j.femsim.2004.01.005
- [51] Abdalla GK, Faria GE, Silva KT, Castro EC, Reis MA, Michelin MA. *Trypanosoma cruzi*: The role of PGE2 in immune response during the acute phase of experimental infection. *Experimental Parasitology*. 2008;**118**(4):514-521. DOI: 10.1016/j.exppara.2007.11.003
- [52] Guerrero NA, Camacho M, Vila L, Iniguez MA, Chillon-Marinhas C, Cuervo H, et al. Cyclooxygenase-2 and Prostaglandin E2 Signaling through Prostaglandin Receptor EP-2 Favor the Development of Myocarditis during Acute *Trypanosoma cruzi* Infection. *PLoS Neglected Tropical Diseases*. 2015;**9**(8):e0004025. DOI: 10.1371/journal.pntd.0004025
- [53] Pavanelli WR, Gutierrez FR, Mariano FS, Prado CM, Ferreira BR, Teixeira MM, et al. 5-lipoxygenase is a key determinant of acute myocardial inflammation and mortality during *Trypanosoma cruzi* infection. *Microbes and Infection*. 2010;**12**(8-9):587-597. DOI: 10.1016/j.micinf.2010.03.016
- [54] Panis C, Mazzuco TL, Costa CZ, Victorino VJ, Tatakihara VL, Yamauchi LM, et al. *Trypanosoma cruzi*: Effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice. *Experimental Parasitology*. 2011;**127**(1):58-65. DOI: 10.1016/j.exppara.2010.06.030
- [55] Celentano AM, Gorelik G, Solana ME, Sterin-Borda L, Borda E, Gonzalez Cappa SM. PGE2 involvement

in experimental infection with *Trypanosoma cruzi* subpopulations. Prostaglandins. 1995;**49**(3):141-153

[56] Cardoni RL, Antunez MI. Circulating levels of cyclooxygenase metabolites in experimental *Trypanosoma cruzi* infections. Mediators of Inflammation. 2004;**13**(4):235-240. DOI: 10.1080/09637480400003022

[57] Pinge-Filho P, Tadokoro CE, Abrahamsohn IA. Prostaglandins mediate suppression of lymphocyte proliferation and cytokine synthesis in acute *Trypanosoma cruzi* infection. Cellular Immunology. 1999;**193**(1):90-98

[58] Michelin MA, Silva JS, Cunha FQ. Inducible cyclooxygenase released prostaglandin mediates immunosuppression in acute phase of experimental *Trypanosoma cruzi* infection. Experimental Parasitology. 2005;**111**(2):71-79. DOI: 10.1016/j.exppara.2005.05.001

[59] Freire-de-Lima CG, Nascimento DO, Soares MB, Bozza PT, Castro-Faria-Neto HC, de Mello FG, et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature. 2000;**403**(6766):199-203. DOI: 10.1038/35003208

[60] Malvezi AD, Panis C, da Silva RV, de Freitas RC, Lovo-Martins MI, Tatakihara VL, et al. Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs *Trypanosoma cruzi* entry into cardiac cells and promotes differential modulation of the inflammatory response. Antimicrobial Agents and Chemotherapy. 2014;**58**(10):6157-6164. DOI: 10.1128/aac.02752-14

[61] Sokolowska M, Chen LY, Liu Y, Martinez-Anton A, Qi HY, Logun C, et al. Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4

receptor and intracellular cyclic AMP in human macrophages. Journal of Immunology. 2015;**194**(11):5472-5487. DOI: 10.4049/jimmunol.1401343

[62] Goncalves VM, Matteucci KC, Buzzo CL, Miollo BH, Ferrante D, Torrecilhas AC, et al. NLRP3 controls *Trypanosoma cruzi* infection through a caspase-1-dependent IL-1R-independent NO production. PLoS Neglected Tropical Diseases. 2013;**7**(10):e2469. DOI: 10.1371/journal.pntd.0002469

[63] Sterin-Borda L, Gorelik G, Goren N, Cappa SG, Celentano AM, Borda E. Lymphocyte muscarinic cholinergic activity and PGE2 involvement in experimental *Trypanosoma cruzi* infection. Clinical Immunology and Immunopathology. 1996;**81**(2):122-128

[64] Mukherjee S, Sadekar N, Ashton AW, Huang H, Spray DC, Lisanti MP, et al. Identification of a functional prostanoic-like receptor in the protozoan parasite, *Trypanosoma cruzi*. Parasitology Research. 2013;**112**(4):1417-1425. DOI: 10.1007/s00436-012-3271-5

[65] Hideko Tatakihara VL, Cecchini R, Borges CL, Malvezi AD, Graca-de Souza VK, Yamada-Ogatta SF, et al. Effects of cyclooxygenase inhibitors on parasite burden, anemia and oxidative stress in murine *Trypanosoma cruzi* infection. FEMS Immunology and Medical Microbiology. 2008;**52**(1):47-58. DOI: 10.1111/j.1574-695X.2007.00340.x

[66] Machado FS, Mukherjee S, Weiss LM, Tanowitz HB, Ashton AW. Bioactive lipids in *Trypanosoma cruzi* infection. Advances in Parasitology. 2011;**76**:1-31. DOI: 10.1016/b978-0-12-385895-5.00001-3

[67] Ashton AW, Mukherjee S, Nagajyothi FN, Huang H, Braunstein VL, Desruisseaux MS, et al. Thromboxane A2 is a key regulator of pathogenesis during *Trypanosoma cruzi*

infection. *The Journal of Experimental Medicine*. 2007;**204**(4):929-940. DOI: 10.1084/jem.20062432

[68] Chapkin RS, Akoh CC, Miller CC. Influence of dietary n-3 fatty acids on macrophage glycerophospholipid molecular species and peptidoleukotriene synthesis. *Journal of Lipid Research*. 1991;**32**(7):1205-1213

[69] Trebble TM, Wootton SA, Miles EA, Mullee M, Arden NK, Ballinger AB, et al. Prostaglandin E2 production and T cell function after fish-oil supplementation: Response to antioxidant cosupplementation. *The American Journal of Clinical Nutrition*. 2003;**78**(3):376-382

[70] Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;**100**(4):1751-1756. DOI: 10.1073/pnas.0334211100

[71] Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature*. 2014;**510**(7503):92-101. DOI: 10.1038/nature13479

[72] Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. *The Journal of Biological Chemistry*. 2003;**278**(17):14677-14687. DOI: 10.1074/jbc.M300218200

[73] Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. *Clinical Chemistry*. 2012;**58**(10):1476-1484. DOI: 10.1373/clinchem.2012.190199

[74] Colas RA, Ashton AW. *Trypanosoma cruzi* produces the specialized proresolving mediators resolvins D1, resolvins D5, and resolvins E2. *Infection and Immunity*. 2018;**86**(4):e00688. DOI: 10.1128/iai.00688-17